COLL vs LLY: fair value comparison
Collegium Pharmaceutical, Inc. and Eli Lilly and Company · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LLY currently sits closer to the top of our discount ranking.
| COLL | LLY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $24.00 | $1,115.70 |
| 12-month range | $24.00–$47.11 | $862.86–$1,160.00 |
| Sector rank | #16 of 113 Healthcare | #14 of 113 Healthcare |
| Quality grade | B | B |
| Leverage | High | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | — |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: COLL fair value analysis · LLY fair value analysis